Association between circulating fibroblast growth factor 21, aerobic fitness, and aortic blood pressure in middle-aged and older women

BACKGROUND: Fibroblast growth factor-21 (FGF21) is known as an important endocrine and paracrine regulator of metabolic homeostasis. Recent studies have shown that FGF21 attenuates lipolysis in human adipocytes, which is suggested as a FGF21's mechanism as anti-hyperlipidemia, anti-hyperglycemia and anti-obesity. The aim of this study was to measure the correlation between FGF21, FFA, hsCRP and HOMA-IR among Indonesian obese non diabetic males.METHOD: The study was observational with cross sectional design. The analysis was done in 137 subjects aged 30-60 years with non diabetic abdominal obesity. We measured the biochemical markers FGF21, FFA, hsCRP, fasting insulin and fasting glucose. We also measured weight, height, waist circumrefence (WC), creatinine, serum glutamin oxaloacetic transaminase (SGOT), and serum glutamic pyruvic transaminase (SGPT), systolic blood pressure (SBP) and diastolic blood pressure (DBP). Correlation between markers was measured using Pearson and Spearman's analysis. RESULT: There were significant positive correlations between FGF21-HOMA-IR (r=0.314, p=0.000); FGF21-WC (r=0.173, p=0.043); FFA=hsCRP (r=0.270, p=0.001); and WC-HOMA-IR (r=0.279, p=0.001). There was significant negative correlation between FGF21-FFA (r=-0.038, p=0.657) and FGF21-hsCRP (r=-0.061, p=0.482). CONCLUSION: In this study we found that although there was no significant correlation, FGF21 might act as an anti-lipolytic and anti-inflammation agent among Indonesian obese non-diabetic males. Our findings agree with results of previous studies that the positive correlation between FGF21-WC and FGF21-HOMA-IR moght occur as a compensatory mechanism or resistance to FGF21 in obesity.KEYWORDS: Obesity, FGF21, FFA, hsCRP, HOMA-IR

Download Full-text

Circulating fibroblast growth factor 21, renal function, and aortic hemodynamics in middle‐aged and older adults: a mediation analysis

The FASEB Journal ◽

10.1096/fasebj.2021.35.s1.05178 ◽

2021 ◽

Vol 35 (S1) ◽

Author(s):

Masahiro Matsui ◽

Keisei Kosaki ◽

Makoto Kuro‐o ◽

Chie Saito ◽

Kunihiro Yamagata ◽

...

Keyword(s):

Older Adults ◽

Renal Function ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Mediation Analysis ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Middle Aged ◽

Aortic Hemodynamics

Download Full-text

Relationship between fibroblast growth factor 21 and lipoproteins in young and middle-aged men with multiple cardiovascular co-morbidities

Arterial’naya Gipertenziya (Arterial Hypertension) ◽

10.18705/1607-419x-2015-21-5-493-499 ◽

2015 ◽

Vol 21 (5) ◽

pp. 493-499

Author(s):

A. S. Partsernyak ◽

M. A. Aflitonov ◽

Yu. Sh. Khalimov ◽

S. A. Partsernyak ◽

A. A. Topanova ◽

...

Keyword(s):

Growth Factor ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Middle Aged

Download Full-text

LBPS 02-06 PLASMA LEVEL OF FIBROBLAST GROWTH FACTOR 21 IS INDEPENDENTLY RELATED TO BLOOD PRESSURE

Journal of Hypertension ◽

10.1097/01.hjh.0000501378.72327.5d ◽

2016 ◽

Vol 34 (Supplement 1) ◽

pp. e507

Author(s):

Bmy Cheung ◽

Chy Fong ◽

C Chen ◽

Awk Cho ◽

Y Wang ◽

...

Keyword(s):

Blood Pressure ◽

Growth Factor ◽

Plasma Level ◽

Fibroblast Growth Factor ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth

Download Full-text

Serum Levels of Fibroblast Growth Factor 21 Are Positively Associated with Aortic Stiffness in Patients with Type 2 Diabetes Mellitus

International Journal of Environmental Research and Public Health ◽

10.3390/ijerph18073434 ◽

2021 ◽

Vol 18 (7) ◽

pp. 3434

Author(s):

Sin-Yi Huang ◽

Du-An Wu ◽

Jen-Pi Tsai ◽

Bang-Gee Hsu

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Aortic Stiffness ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth

Aortic stiffness (AS), assessed using carotid–femoral pulse wave velocity (cfPWV), is associated with cardiovascular disease in type 2 diabetes mellitus (T2DM). The relationship between serum fibroblast growth factor 21 (FGF-21) and AS in T2DM patients was evaluated. Fasting serum FGF-21 levels of 130 T2DM patients were measured using an enzyme immunoassay kit. A validated tonometry system was used to measure cfPWV (>10 m/s indicated AS). Of these T2DM patients, 34.6% were defined as the AS group. T2DM patients with AS were older; exhibited higher systolic blood pressure, diastolic blood pressure, and body fat mass; higher triglyceride, fasting glucose, glycosylated hemoglobin, and creatinine levels; higher urine albumin-to-creatinine ratios and serum FGF-21 levels; and lower estimated glomerular filtration rates. The FGF-21 level (odds ratio = 1.005, 95% confidence interval: 1.002–1.009, p = 0.002) as well as systolic blood pressure was an independent predictor of AS and positively correlated to cfPWV values (β = 0.369, p < 0.001) in T2DM patients. For T2DM patients, serum FGF-21 level could be a predictor for AS.

Download Full-text

High-Level Serum Fibroblast Growth Factor 21 Concentration Is Closely Associated With an Increased Risk of Cardiovascular Diseases: A Systematic Review and Meta-Analysis

Frontiers in Cardiovascular Medicine ◽

10.3389/fcvm.2021.705273 ◽

2021 ◽

Vol 8 ◽

Author(s):

Yucong Zhang ◽

Jinhua Yan ◽

Ni Yang ◽

Zonghao Qian ◽

Hao Nie ◽

...

Keyword(s):

Systematic Review ◽

Blood Pressure ◽

Growth Factor ◽

Fibroblast Growth Factor ◽

Meta Analysis ◽

Fibroblast Growth Factor 21 ◽

Fibroblast Growth ◽

Cvd Risk ◽

Increased Risk ◽

High Level

Background: The association between fibroblast growth factor 21 (FGF21) and cardiovascular disease (CVD) risk remains unclear. We conducted this systematic review and meta-analysis to evaluate the association between FGF21 and CVDs, and relevant vascular parameters.Methods: PubMed and Web of Science databases were systematically searched to identify relevant studies published before March 2021. The FGF21 concentration was compared between individuals with and without CVDs. The effect of FGF21 on CVD risk was assessed by using hazard ratio (HR) and odds ratio (OR). The association between FGF21 and vascular parameters was assessed by Pearson's r. Study quality was assessed using Newcastle–Ottawa Scale and Joanna Briggs Institution Checklist.Results: A total of 29,156 individuals from 30 studies were included. Overall, the serum FGF21 concentration was significantly higher in CVD patients (p < 0.001), especially for coronary artery disease (CAD) (p < 0.001) and hypertension (p < 0.001). The pooled OR (p = 0.009) and HR (p < 0.001) showed that the risk of CVDs increased with FGF21. The linear association between FGF21 and vascular parameters, including pulse wave velocity (r = 0.32), carotid intima-media thickness (r = 0.21), ankle-brachial index (r = 0.33), systolic blood pressure (r = 0.13), and diastolic blood pressure (r = 0.05), was insignificant. The incidence of overall CVDs (p = 0.03) was significantly higher in individuals with higher FGF21 levels.Conclusion: High-level serum FGF21 concentration is closely associated with an increased risk of CVDs, which may be independent of vascular parameters. A standard FGF21 classification threshold needs to be established before clinical use for CVD risk assessment.Systematic Review Registration:https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=241968, identifier: CRD42021241968.

Download Full-text